Eckert & Ziegler and IBt to consolidate Implant Businesses

ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Merger
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Berlin, 28 February 2008 – Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) and IBt s.a. have reached an agreement about the consolidation of their respective Businesses for Prostate Cancer Implants and executed a Share Contribution Agreement, in which Eckert & Ziegler sells its Implant Business to IBt with immediate effect in exchange for 6.75 million IBt shares. As a result, Eckert & Ziegler will become IBt’s largest shareholder, owning about 40% of all rights to dividends and other economic benefits, and close to 30% of the voting rights in IBt’s shareholder meeting. The difference in the two ratios is due to the existence of so-called Beneficiary Shares, which only convey voting rights in the shareholder meeting, but not to dividends.
Further details are provided in a press release which is available on the company’s homepage.

The Executive Board


For enquiries please contact:
Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 94 10 84-139, Fax -112, E-mail: thomas.scheuch@ezag.de, www.ezag.de



28.02.2008  Financial News transmitted by DGAP

---

 
Language:     English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG               Robert-Rössle-Str. 10
              13125 Berlin
              Deutschland
Phone:        +49 (0)30 941 084-0
Fax:          +49 (0)30 941 084-112
E-mail:       thomas.scheuch@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700
WKN:          565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Hamburg, Düsseldorf  
End of News DGAP News-Service  

---